Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Abstract

In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo. (Funded by Pfizer; ATTR-ACT ClinicalTrials.gov number, NCT01994889 .).

Keywords

TransthyretinHazard ratioMedicinePlaceboInternal medicineClinical endpointConfidence intervalCardiomyopathyGastroenterologyCardiologyClinical trialHeart failurePathology

Affiliated Institutions

Related Publications

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott , Itamar Raz , Marc P. Bonaca +17 more

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

2018 New England Journal of Medicine 5890 citations

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker , Javed Butler , Gerasimos Filippatos +38 more

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless...

2021 New England Journal of Medicine 4054 citations

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer , Stefan D. Anker , Javed Butler +36 more

Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure th...

2020 New England Journal of Medicine 4558 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials

Costas Thomopoulos , Gianfranco Parati , Alberto Zanchetti

Meta-analyses of all BP-lowering RCTs involving hypertensive patients provide precise estimates of benefits (larger for stroke and heart failure, but also significant for CHD an...

2014 Journal of Hypertension 364 citations

Publication Info

Year: 2018
Type: article
Volume: 379
Issue: 11
Pages: 1007-1016
Citations: 2458
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2458

OpenAlex

Cite This

APA Style

                            
                                
                                    Matthew J. Maurer, 
                                
                                    Jeffrey H. Schwartz, 
                                
                                    Balarama Gundapaneni
                                
                                et al.
                            
                            (2018). 
                            Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. 
                            New England Journal of Medicine
                            , 379
                            (11)
                            , 1007-1016.
                            https://doi.org/10.1056/nejmoa1805689
                        

Identifiers

DOI: 10.1056/nejmoa1805689